ArticleMolecular psychiatry2026
Mendelian randomization facilitates identification of schizophrenia risk enhancer RNAs.
Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The transcription of enhancer RNA (eRNA) marks enhancer activity and may confer context-dependent regulatory functions, yet its underlying mechanism remains elusive. Leveraging BrainSeq data, we constructed ancestry-stratified expression quantitative trait locus (eQTL) maps for 71,022 transcriptional non-coding enhancer (TNE) RNAs. By integrating the latest Psychiatric Genomics Consortium (PGC3) schizophrenia GWAS with European-ancestry population-based eQTLs via Summary-data-based Mendelian Randomization (SMR), we identified 61 schizophrenia-risk TNEs, 19 of which overlapped with those from differential expression (DE) analysis. Intriguingly, for 19 overlapping TNEs, effects from DE analysis were inversely correlated with SMR effects (r = -0.57, P = 0.01), attributable to the opposing contributions of phenotype and genotype to TNE expression (r = -0.78, P = 2.96E-3). We further linked this discrepancy to reduced levels of the repressor ZNF135 in schizophrenia, which derepressed motif-matched TNEs. Finally, we identified and experimentally validated that an enhancer RNA within the intronic region of RGS6, termed RGS6e, regulates the expression of genes associated with the nervous system through trans-acting mechanisms, promoting neuronal differentiation and thereby reducing the risk of schizophrenia, consistent with the SMR results. This study underscores the significance of eQTL-based SMR analysis in elucidating the role of enhancers and their transcriptional products in schizophrenia risk. The eQTL map of TNEs developed in our study holds considerable potential for application in enhancer research related to other mental diseases or neurodegenerative diseases, thereby enhancing our understanding of how enhancers contribute to disease pathogenesis and progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.